Richard B. Stead

1.1k total citations
22 papers, 776 citations indexed

About

Richard B. Stead is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Richard B. Stead has authored 22 papers receiving a total of 776 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 6 papers in Oncology and 5 papers in Genetics. Recurrent topics in Richard B. Stead's work include Erythropoietin and Anemia Treatment (8 papers), Platelet Disorders and Treatments (5 papers) and Neutropenia and Cancer Infections (5 papers). Richard B. Stead is often cited by papers focused on Erythropoietin and Anemia Treatment (8 papers), Platelet Disorders and Treatments (5 papers) and Neutropenia and Cancer Infections (5 papers). Richard B. Stead collaborates with scholars based in United States, United Kingdom and Belgium. Richard B. Stead's co-authors include Karl E. Anderson, Richard W. Carson, Douglas E. Goeger, Anne‐Marie Duliège, Nicole Casadevall, Iain C. Macdougall, Peter J. Schatz, Kathryn W. Woodburn, Marc Froissart and Jérôme Rossert and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Richard B. Stead

22 papers receiving 746 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard B. Stead United States	12	511	129	121	112	108	22	776
Peter A.W. te Boekhorst Netherlands	21	582 1.1×	245 1.9×	113 0.9×	208 1.9×	263 2.4×	50	1.1k
Richard H. Aster United States	20	1.2k 2.3×	88 0.7×	178 1.5×	115 1.0×	34 0.3×	41	1.3k
Harold C. Sullivan United States	16	254 0.5×	49 0.4×	166 1.4×	31 0.3×	198 1.8×	43	828
Jennifer Herring United States	11	153 0.3×	81 0.6×	62 0.5×	68 0.6×	347 3.2×	21	788
Jan Roodt South Africa	16	586 1.1×	131 1.0×	326 2.7×	138 1.2×	20 0.2×	30	980
Nicholas Wickham Australia	16	292 0.6×	174 1.3×	86 0.7×	16 0.1×	130 1.2×	35	804
Irene Marini Germany	11	278 0.5×	50 0.4×	56 0.5×	47 0.4×	57 0.5×	28	539
Andrew Belch United States	15	839 1.6×	239 1.9×	106 0.9×	75 0.7×	535 5.0×	32	1.1k
Marion Sternbach Canada	10	263 0.5×	98 0.8×	138 1.1×	21 0.2×	126 1.2×	17	529
Balkis Meddeb Tunisia	13	774 1.5×	241 1.9×	86 0.7×	25 0.2×	104 1.0×	50	1.0k

Countries citing papers authored by Richard B. Stead

Since Specialization

Citations

This map shows the geographic impact of Richard B. Stead's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard B. Stead with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard B. Stead more than expected).

Fields of papers citing papers by Richard B. Stead

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard B. Stead. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard B. Stead. The network helps show where Richard B. Stead may publish in the future.

Co-authorship network of co-authors of Richard B. Stead

This figure shows the co-authorship network connecting the top 25 collaborators of Richard B. Stead. A scholar is included among the top collaborators of Richard B. Stead based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard B. Stead. Richard B. Stead is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Melief, Cornelis J.M., Winald R. Gerritsen, Marij J.P. Welters, et al.. (2017). Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer.. Journal of Clinical Oncology. 35(7_suppl). 140–140. 4 indexed citations

2.

Gerritsen, Winald R., Cornelis J.M. Melief, Marij J.P. Welters, et al.. (2017). Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival.. Journal of Clinical Oncology. 35(15_suppl). 5525–5525. 8 indexed citations

3.

Farese, Ann M., Melanie Cohen, Richard B. Stead, William E. Jackson, & Thomas J. MacVittie. (2012). Pegfilgrastim Administered in an Abbreviated Schedule, Significantly Improved Neutrophil Recovery after High-Dose Radiation-Induced Myelosuppression in Rhesus Macaques. Radiation Research. 178(5). 403–413. 50 indexed citations

4.

Macdougall, Iain C., Jérôme Rossert, Nicole Casadevall, et al.. (2009). A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia. New England Journal of Medicine. 361(19). 1848–1855. 95 indexed citations

5.

Woodburn, Kathryn W., Qing Fan, Minjia Chen, et al.. (2007). Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Experimental Hematology. 35(8). 1201–1208. 48 indexed citations

6.

Pickering, Lisa, Karel Cwiertka, Jacek Jassem, et al.. (2007). Correction of Anemia with Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), in Oncology Patients Receiving Chemotherapy.. Blood. 110(11). 3666–3666. 5 indexed citations

7.

Stead, Richard B., John S. Lambert, Julie Iwashita, et al.. (2006). Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 108(6). 1830–1834. 88 indexed citations

8.

Pickering, Lisa, Karel Cwiertka, Jacek Jassem, et al.. (2006). HematideTM, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Assessed for Correction of Anemia in Oncology Patients Receiving Chemotherapy.. Blood. 108(11). 1290–1290. 2 indexed citations

9.

Stead, Richard B., José Luis Lambert, D. H. Wessels, et al.. (2005). A synthetic peptide-based erythropoiesis stimulating agent (ESA) (Hematide) demonstrates dose dependent activity and is well tolerated in a phase 1 single dose, dose escalating study in normal healthy volunteers (NHV). Journal of Clinical Oncology. 23(16_suppl). 8180–8180. 3 indexed citations

10.

Duliège, Anne‐Marie, Iain C. Macdougall, Neill Duncan, et al.. (2005). Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Demonstrates Erythropoietic Activity in a Phase 2 Single Dose, Dose Escalating Study in Patients with Chronic Kidney Disease (CKD).. Blood. 106(11). 3532–3532. 11 indexed citations

11.

Harker, Laurence A., Ulla M. Marzec, Francis J. Novembre, et al.. (1998). Treatment of Thrombocytopenia in Chimpanzees Infected With Human Immunodeficiency Virus by Pegylated Recombinant Human Megakaryocyte Growth and Development Factor. Blood. 91(12). 4427–4433. 5 indexed citations

12.

Harker, Laurence A., Ulla M. Marzec, Francis J. Novembre, et al.. (1998). Treatment of Thrombocytopenia in Chimpanzees Infected With Human Immunodeficiency Virus by Pegylated Recombinant Human Megakaryocyte Growth and Development Factor. Blood. 91(12). 4427–4433. 34 indexed citations

13.

Harker, Laurence A., Ulla M. Marzec, Andrew B. Kelly, et al.. (1997). Prevention of Thrombocytopenia and Neutropenia in a Nonhuman Primate Model of Marrow Suppressive Chemotherapy by Combining Pegylated Recombinant Human Megakaryocyte Growth and Development Factor and Recombinant Human Granulocyte Colony-Stimulating Factor. Blood. 89(1). 155–165. 43 indexed citations

14.

Harker, Laurence A., Ulla M. Marzec, Andrew B. Kelly, et al.. (1997). Prevention of Thrombocytopenia and Neutropenia in a Nonhuman Primate Model of Marrow Suppressive Chemotherapy by Combining Pegylated Recombinant Human Megakaryocyte Growth and Development Factor and Recombinant Human Granulocyte Colony-Stimulating Factor. Blood. 89(1). 155–165. 3 indexed citations

15.

Stead, Richard B. & Laurence A. Harker. (1996). Preclinical studies and potential clinical applications of c-mpl ligand. Current Opinion in Hematology. 3(3). 197–202. 3 indexed citations

16.

Meisenberg, BR, et al.. (1992). A comparison of therapeutic schedules for administering granulocyte colony-stimulating factor to nonhuman primates after high-dose chemotherapy. Blood. 79(9). 2267–2272. 24 indexed citations

17.

Meisenberg, BR, et al.. (1992). A comparison of therapeutic schedules for administering granulocyte colony-stimulating factor to nonhuman primates after high-dose chemotherapy. Blood. 79(9). 2267–2272. 21 indexed citations

18.

Anderson, Karl E., et al.. (1990). Erythropoietin for the Treatment of Porphyria Cutanea Tarda in a Patient on Long-Term Hemodialysis. New England Journal of Medicine. 322(5). 315–317. 277 indexed citations

19.

Schuening, Friedrich, R Storb, Richard A. Nash, et al.. (1988). Retroviral Transfer of Genes into Canine Hematopoietic Progenitor Cells. Advances in experimental medicine and biology. 241. 9–18. 5 indexed citations

20.

Stead, Richard B., Andrew I. Schafer, Robert Rosenberg, et al.. (1984). Heterogeneity of heparin lots associated with thrombocytopenia and thromboembolism. The American Journal of Medicine. 77(1). 185–188. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact